NCT02596308View on ClinicalTrials.gov

Immunogenicity and Safety of Subunit Plague Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Plague
Interventions
BIOLOGICAL

Plague vaccine

Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Lanzhou Institute of Biological Products Co., Ltd

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT02596308 - Immunogenicity and Safety of Subunit Plague Vaccine | Biotech Hunter | Biotech Hunter